MSBMesoblast

Mesoblast shares surged after the company announced it had enrolled 300 patients in its Phase 3 back pain trial, hitting a key milestone, while continuing momentum from a recent strong Ryoncil commercial launch and FDA BLA progress drove sustained buying interest.

Mesoblast shares rose sharply, most likely driven by company-specific news or clinical trial developments not captured in available data sources, as the move is too large to be explained by broad market or sector tailwinds alone.

The stock dropped after a 5% slide report on Friday, continuing a pullback following a recent non-dilutive funding drawdown announcement.

Mesoblast announced the launch of a pivotal adult trial for its cell therapy in severe steroid-refractory GVHD, driving investor optimism.

Mesoblast's founder publicly refuted short sellers, likely triggering a short squeeze.

Mesoblast shares rose sharply on October 7, 2025, as part of a broad market rally that included several stocks, with no company-specific news identified.